The CRIS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CRIS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CRIS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CRIS Detailed Price Forecast - CNN Money||View CRIS Detailed Summary - Google Finance|
|View CRIS Detailed Summary - Yahoo! Finance||View CRIS Stock Research & Analysis - Zacks.com|
|View CRIS Trends & Analysis - Trade-Ideas||View CRIS Major Holders - Barrons|
|View CRIS Call Transcripts - NASDAQ||View CRIS Breaking News & Analysis - Seeking Alpha|
|View CRIS Annual Report - CompanySpotlight.com||View CRIS OTC Short Report - OTCShortReport.com|
|View CRIS Fundamentals - TradeKing||View CRIS SEC Filings - Bar Chart|
|View Historical Prices for CRIS - The WSJ||View Performance/Total Return for CRIS - Morningstar|
|View the Analyst Estimates for CRIS - MarketWatch||View the Earnings History for CRIS - CNBC|
|View the CRIS Earnings - StockMarketWatch||View CRIS Buy or Sell Recommendations - MacroAxis|
|View the CRIS Bullish Patterns - American Bulls||View CRIS Short Pain Metrics - ShortPainBot.com|
|View CRIS Stock Mentions - StockTwits||View CRIS Stock Mentions - PennyStockTweets|
|View CRIS Stock Mentions - Twitter||View CRIS Investment Forum News - Investor Hub|
|View CRIS Stock Mentions - Yahoo! Message Board||View CRIS Stock Mentions - Seeking Alpha|
|View Insider Transactions for CRIS - SECform4.com||View Insider Transactions for CRIS - Insider Cow|
|View CRIS Major Holdings Summary - CNBC||View Insider Disclosure for CRIS - OTC Markets|
|View Insider Transactions for CRIS - Yahoo! Finance||View Institutional Holdings for CRIS - NASDAQ|
|View CRIS Stock Insight & Charts - FinViz.com||View CRIS Investment Charts - StockCharts.com|
|View CRIS Stock Overview & Charts - BarChart||View CRIS User Generated Charts - Trading View|
Curis to Release First Quarter 2018 Financial Results and Hold Conference Call on May 3, 2018
Posted on Thursday April 26, 2018
LEXINGTON, Mass., April 26, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2018 financial results on Thursday, May 3, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT. Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors.
Are Earnings Prospects Improving For Loss-Making Curis Inc’s (NASDAQ:CRIS)?
Posted on Friday April 20, 2018
Improvement in profitability and outperformance against the industry can be important characteristics in a stock for some investors. Below, I will assess Curis Inc’s (NASDAQ:CRIS) track record on a highRead More...
Free Post Earnings Research Report: Curis’ Quarterly Revenue Jumped 38.10%
Posted on Thursday April 19, 2018
Stock Monitor: Aldeyra Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free earnings report on Curis, Inc. (NASDAQ: CRIS ). If you ...
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Posted on Friday April 06, 2018
LEXINGTON, Mass., April 6, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that on April 2, 2018, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 250,000 shares of Curis common stock to three new employees, with a grant date of April 2, 2018 (the "Q2 2018 Inducement Grants").